Wegovy is under clinical development by Novo Nordisk and currently in Pre-Registration for Diastolic Heart Failure (HFpEF). According to GlobalData, Pre-Registration drugs for Diastolic Heart Failure (HFpEF) does not have sufficient historical data to build an indication benchmark PTSR for Pre-Registration. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Wegovy LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Wegovy overview

Semaglutide (Wegovy, Wegovy Flextouch, Wegovy FixDose, Wegovy Multi FixDose) is a recombinant peptide and analogue of human glucagon-like peptide-1 (GLP-1). It is formulated as an injection solution for the subcutaneous route of administration. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Semaglutide (NN-9536) is under development for the treatment of obesity and obesity-related heart failure with preserved ejection fraction (cardiovascular disease). It is administered subcutaneously as a long acting once-weekly formulation. The drug candidate is a GLP-1 analogue which targets glucagon-like peptide 1 receptor (GLP1R).

Novo Nordisk overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company with focus on discovering, developing, and manufacturing biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious and chronic conditions including haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for haemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

For a complete picture of Wegovy’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.